Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

EHU018671

Sigma-Aldrich

MISSION® esiRNA

targeting human SMAD4

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización

Seleccione un Tamaño

20 μG
MXP 5,935.00
50 μG
MXP 10,600.00

MXP 5,935.00

Check Cart for Availability
Todas las fotos(1)

Seleccione un Tamaño

Cambiar Vistas
20 μG
MXP 5,935.00
50 μG
MXP 10,600.00

About This Item

Código UNSPSC:
41105324
NACRES:
NA.51

MXP 5,935.00

Check Cart for Availability

descripción

Powered by Eupheria Biotech

Línea del producto

MISSION®

Formulario

lyophilized powder

secuencia objetivo ADNc esiRNA

TGTGCCATAGACAAGGTGGAGAGAGTGAAACATTTGCAAAAAGAGCAATTGAAAGTTTGGTAAAGAAGCTGAAGGAGAAAAAAGATGAATTGGATTCTTTAATAACAGCTATAACTACAAATGGAGCTCATCCTAGTAAATGTGTTACCATACAGAGAACATTGGATGGGAGGCTTCAGGTGGCTGGTCGGAAAGGATTTCCTCATGTGATCTATGCCCGTCTCTGGAGGTGGCCTGATCTTCACAAAAATGAACTAAAACATGTTAAATATTGTCAGTATGCGTTTGACTTAAAATGTGATAGTGTCTGTGTGAATCCATATCACTACGAACGAGTTGTATCACCTGGAATTGATCTCTCAGGATTAACACTGCAGAGTAATGCTCCATCAAGTATGATGGTGAAGGATGAATATGTGCATGACTTTGAGGGACAGCCATCGTTGTCCACTGAAGGACATTCAATTCAAACCATCCAGCATCCACCAAGTAATCGTGCATCG

Ensembl | nº de acceso humano

ENSG00000141646

Nº de acceso NCBI

NM_005359

Condiciones de envío

ambient

temp. de almacenamiento

−20°C

Información sobre el gen

human ... SMAD4(4089) , SMAD4(4089)

Comparar elementos similares

Ver comparación completa

Mostrar Diferencias

1 of 4

Este artículo
EHU021611EHU028081EHU037241
MISSION® esiRNA targeting human SMAD4

EHU018671

MISSION® esiRNA

MISSION® esiRNA targeting human SMYD4

EHU021611

MISSION® esiRNA

MISSION® esiRNA targeting human NPY5R

EHU028081

MISSION® esiRNA

MISSION® esiRNA targeting human SMAD3

EHU037241

MISSION® esiRNA

Ensembl | human accession no.

ENSG00000141646

Ensembl | human accession no.

ENSG00000186532

Ensembl | human accession no.

ENSG00000164129

Ensembl | human accession no.

ENSG00000166949

product line

MISSION®

product line

MISSION®

product line

MISSION®

product line

MISSION®

esiRNA cDNA target sequence

TGTGCCATAGACAAGGTGGAGAGAGTGAAACATTTGCAAAAAGAGCAATTGAAAGTTTGGTAAAGAAGCTGAAGGAGAAAAAAGATGAATTGGATTCTTTAATAACAGCTATAACTACAAATGGAGCTCATCCTAGTAAATGTGTTACCATACAGAGAACATTGGATGGGAGGCTTCAGGTGGCTGGTCGGAAAGGATTTCCTCATGTGATCTATGCCCGTCTCTGGAGGTGGCCTGATCTTCACAAAAATGAACTAAAACATGTTAAATATTGTCAGTATGCGTTTGACTTAAAATGTGATAGTGTCTGTGTGAATCCATATCACTACGAACGAGTTGTATCACCTGGAATTGATCTCTCAGGATTAACACTGCAGAGTAATGCTCCATCAAGTATGATGGTGAAGGATGAATATGTGCATGACTTTGAGGGACAGCCATCGTTGTCCACTGAAGGACATTCAATTCAAACCATCCAGCATCCACCAAGTAATCGTGCATCG

esiRNA cDNA target sequence

CTGCTTCAAAAGTGGGCTTCACTCCCGACGTCTGTTCAGGTCACAATTTCTACAGCAGAGACCTTGAGGGATATCTTTCTTCACTCCTCTTCACTTCTTCAACCTGAGGATGAGCTGTTTCTAAAAAGACTTTCTAAAGGTTACTTGGTGGGAAAGGACTCGGACGCTCCTCTTTTCTACAGAGAAGAAGGAAACAAAAAATTTCAGGAGAAAGATTACACAGGAGCTGCAGTGCTGTACTCTAAGGGAGTGTCACATTCAAGGCCTAACACTGAGGACATGTCACTGTGTCATGCTAACCGCTCGGCAGCCCTCTTCCACCTGGGTCAGTATGAGACGTGTCTTAAAGACATTAACAGAGCACAGACACATGGGTATCCAGAAAGGTTGCAACCCAAGATTATGTTACGTAAAGCAGAATGTCTGGTGGCCCTGGGGAGACTGCAGGAGGCAAGCCAGACCATCAGTGATCTTGAAAGGAACTTCACAGCCACACC

esiRNA cDNA target sequence

TGGATGCCACTACACCTTTTCCATGTGGTAACTGATTTTAATGACAATCTTATTTCAAATAGGCATTTCAAGTTGGTGTATTGCATTTGTCATTTGTTGGGCATGATGTCCTGTTGTCTTAATCCAATTCTATATGGGTTTCTTAATAATGGGATTAAAGCTGATTTAGTGTCCCTTATACACTGTCTTCATATGTAATAATTCTCACTGTTTACCAAGGAAAGAACAAATGCTGGGGTCATATAAAATATATTTATGATAACTATTTACATATAATAAATAGAAATTTTGTTAACATGGAATTTAATTTATGTGAAAGAGTTCTGGATTCAAATGTCAGTTCATAATATATGGAAGATAATTTTATGTGTTATAGTAGGATTAATTTATTTAGTTGTGCAGTCAGTGTCAATCCAA

esiRNA cDNA target sequence

GGCTTTGAGGCTGTCTACCAGTTGACCCGAATGTGCACCATCCGCATGAGCTTCGTCAAAGGCTGGGGAGCGGAGTACAGGAGACAGACTGTGACCAGTACCCCCTGCTGGATTGAGCTGCACCTGAATGGGCCTTTGCAGTGGCTTGACAAGGTCCTCACCCAGATGGGCTCCCCAAGCATCCGCTGTTCCAGTGTGTCTTAGAGACATCAAGTATGGTAGGGGAGGGCAGGCTTGGGGAAAATGGCCATGCAGGAGGTGGAGAAAATTGGAACTCTACTCAACCCATTGTTGTCAAGGAAGAAGAAATCTTTCTCCCTCAACTGAAGGGGTGCACCCACCTGTTTTCTGAAACACACGAGCAAACCCAGAGGTGGATGTTATGAACAGCTGTGTCTGCCAAACACATTTACCCTTTGGCCCCACTTTGAAGGGCAAGAAATGGCGTCTGCTCTGGTGGCTTAAGTGA

NCBI accession no.

NM_005359

NCBI accession no.

NM_052928

NCBI accession no.

NM_006174

NCBI accession no.

NM_005902

storage temp.

−20°C

storage temp.

−20°C

storage temp.

−20°C

storage temp.

−20°C

Descripción general

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Información legal

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Código de clase de almacenamiento

12 - Non Combustible Liquids

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
FDV
PCV
YBV
MOU
RNU

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Ryotaro Ogawa et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 25(9), 2887-2899 (2019-02-02)
SMAD4 is a key transcriptional factor of TGFβ signaling and acts as a tumor suppressor in colorectal cancer. In the present study, we explored the immunologic effect of SMAD4 on the tumor microenvironment. Using 99 clinical specimens and human colorectal
Mao Ding et al.
Journal of experimental & clinical cancer research : CR, 39(1), 28-28 (2020-02-06)
Sirtuin-7 (SIRT7) is associated with the maintenance of tumorigenesis. However, its functional roles and oncogenic mechanisms in prostate cancer (PCa) are poorly understood. Here, we investigated the roles and underlying molecular mechanisms of SIRT7 in PCa cell growth and androgen-induced
Xiaojiang Tang et al.
Journal of cellular biochemistry, 121(11), 4642-4653 (2020-02-13)
As an aggressive breast cancer (BCa) subtype, triple-negative breast cancer (TNBC) responses poorly to chemotherapy and endocrine therapy, and usually has a worse prognosis. This is largely due to the lack of specific therapeutic targets, laying claim to an imperious
Qing Xie et al.
Scientific reports, 7, 42840-42840 (2017-02-17)
Increasing evidence has indicated that bone morphogenetic protein 2 (BMP2) coordinates with microRNAs (miRNAs) to form intracellular networks regulating mesenchymal stem cells (MSCs) osteogenesis. This study aimed to identify specific miRNAs in rat adipose-derived mesenchymal stem cells (ADSCs) during BMP2-induced
Arundhati Jana et al.
Oncotarget, 8(23), 37377-37393 (2017-04-19)
Colorectal cancer (CRC) remains a common and deadly cancer due to metastatic disease. Activin and TGFB (TGFβ) signaling are growth suppressive pathways that exert non-canonical pro-metastatic effects late in CRC carcinogenesis. We have recently shown that activin downregulates p21 via
Ver todos los artículos relacionados

Questions

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico